From Yahoo Finance: 2025-04-01 09:52:00

In 2024, healthcare stocks faced challenges due to market uncertainties and policy issues, with certain segments struggling with supply and demand imbalances caused by the pandemic. Despite this, the sector showed improvement in the latter half of the year, driven by increased demand for delayed medical procedures. Innovation in biotech and pharmaceuticals remained strong.

In the first quarter of 2025, healthcare stocks outperformed the broader market, marking a significant contrast to previous years of modest growth. The healthcare sector remains vital to the economy, driven by increasing demand for medical products and services due to an aging population. Despite challenges, healthcare ranks as the fourth largest sector in the market.

Investors are cautious about potential policy shifts under the new administration, particularly in relation to healthcare companies facing greater scrutiny. Concerns arise over potential budget cuts that could impact healthcare organizations. Hospital mergers and acquisitions are rebounding despite strict antitrust policies, as regulatory changes may influence future M&A activity.

Bristol-Myers Squibb Company (NYSE:BMY) is among the best healthcare stocks to buy according to billionaires, ranking 8th on the list. In 2024, BMY experienced strong revenue growth driven by key products like BREYANZI and Opdivo. The company maintained solid financials and received approval for Breyanzi, a CAR T cell therapy for certain lymphoma patients. Investors are advised to consider AI stocks for potentially higher returns.



Read more at Yahoo Finance: Is Bristol-Myers Squibb (BMY) One of the Best Healthcare Stocks to Buy According to Billionaires?